Category Archives: Generics / ANDA

Impax Laboratories Inc., AstraZeneca AB et al. V. Lannett Holdings Inc. et al.

Docket No. 2017-2020 LOURIE, DYK, TARANTO June 28, 2018 Brief summary: DC finding that Impax’s (AZ’s) patents encompassing the migraine drug Zomig® were not invalid for obviousness affirmed (agreeing with the DC “that this case was close”). Summary: Lannex appealed … Continue reading

Posted in Generics / ANDA, Obviousness, Obviousness-Teaching Away | Leave a comment

UCB, Inc. et al. v Accord Healthcare et al.

Docket No. 2017-1909, -1910 REYNA, CLEVENGER, WALLACH May 21, 2018 Brief summary: DC decision of no invalidity of UCB’s OB claims covering the anti-epileptic Vimpat® affirmed. Summary: Accord appealed DC decision that UCB’s RE38,551 covering the anti-epileptic functionalized amino acid … Continue reading

Posted in Anticipation (35 USC 102), Double Patenting, Generics / ANDA, Obviousness | Leave a comment

Endo Pharmaceuticals, Inc., Grunenthal GmbH v. Teva Pharm. USA, et al.

Docket No. 2015-2021(22 others) MOORE, BRYSON, HUGHES May 16, 2018 Non-precedential Brief summary: DC findings that the proposed ANDA of Endo’s OPANA®ER infringe the claims, and that those claims are not invalid for obviousness or indefiniteness, affirmed. Summary: Teva et … Continue reading

Posted in Generics / ANDA, Indefiniteness, Infringement, Injunction, Obviousness | Leave a comment

ICOS Corporation v. Actelion Pharmaceuticals Ltd.

Docket No. 2017-1017, -1018 (IPR2015-00561, -00562) MOORE, LINN, CHEN April 18, 2018 Non-precedential Brief summary: PTAB findings of invalidity for obviousness of the claims of ICOS’ Orange Book-listed patents for tadalafil (Eli Lilly’s Cialis®) affirmed. Summary: ICOS appealed PTAB IPR … Continue reading

Posted in Generics / ANDA, Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment

Sumimoto Dainippon Pharma Co./Sunovion Pharm. v. Emcure Pharmaceuticals et al.

Docket No. 2017-1798-800 MOORE, MAYER, STOLL April 16, 2018 Brief summary: DC determination that Sumimoto’s US 5,532,372 relating to Sunovion’s schizophrenia and bipolar depression drug LATUDA® (lurasidone) is not limited to racemic mixture affirmed. Summary: Emcure appealed DC determination that … Continue reading

Posted in Claim Construction, Generics / ANDA, Prosecution History Estoppel | Leave a comment

Vanda Pharm. Inc. v. West-Ward Pharm. Int. Ltd. et al.

Docket No. 2016-2707, -2708 PROST, LOURIE, HUGHES April 13, 2018 Brief summary: DC finding of infringement of later-issued OB patent by amended ANDA, and that method of treatment claims are patentable under § 101 affirmed. Summary: WW appealed DC holding … Continue reading

Posted in Generics / ANDA, Inducement to Infringe, Infringement, Jurisdiction, Patentability, Written description | Leave a comment

Aptalis Pharmatech, Inc., Ivax Int. GmbH v. Apotex Inc. et al.

Docket Nos. 2017-1344 REYNA, WALLACH, STOLL January 4, 2018 Non-precedential Brief summary: DC claim construction of extended release coating as not “continuous”, and corresponding finding of infringement, vacated and remanded. Summary: Apotex appealed from DC construction of “extended release coating” … Continue reading

Posted in Claim Construction, Generics / ANDA | Leave a comment